

510969
Rec'd PCT/PTO 12 OCT 2004

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087404 A1

(51) International Patent Classification⁷: **C12Q 1/68**

Hristos [US/US]; 11300 Ridge Mist Terrace, Potomac, MD 20854 (US).

(21) International Application Number: **PCT/EP03/04007**

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date: **16 April 2003 (16.04.2003)**

(25) Filing Language: **English**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(26) Publication Language: **English**

(30) Priority Data:
60/373,206 17 April 2002 (17.04.2002) US
60/431,583 6 December 2002 (06.12.2002) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except AT, US*): **NO-VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DRESSMAN, Marlene, Michelle** [US/US]; 18005 Red Rocks Drive, Germantown, MD 20874 (US). **MCLEAN, Lee, Anne** [US/US]; 20412 Shore Harbour Drive, Unit 7A, Germantown, MD 20874 (US). **POLYMEROPOULOS, Mihael**,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHODS TO PREDICT PATIENT RESPONSIVENESS TO TYROSINE KINASE INHIBITORS**

(57) Abstract: This invention relates to the use of two form of genomic analysis to predict responsiveness of patients with tyrosine kinase responsive such as Philadelphia chromosome-positive leukemia to treatment with tyrosine kinase inhibitor drugs.

BEST AVAILABLE COPY

WO 03/087404 A1